Author Affiliations: Center for Health Policy and Outcomes, Memorial Sloan-Kettering Cancer Center, New York, New York (Dr Bach); and Department of Emergency Medicine, Harbor-University of California Los Angeles Medical Center, Torrance (Dr Lewis).
In this issue of JAMA, Gaziano and colleagues1 report one of several analyses of data from the Physicians' Health Study II (PHS II) randomized controlled trial. Among more than 14 000 male physicians who participated in this study, the authors report a marginally statistically significant (P = .04) inverse relationship between taking a daily multivitamin (Centrum Silver) and the occurrence of cancer.1 The authors did not find that the supplement prevented any particular cancer preferentially, and there was no evidence of an association between adherence and the protective effect. The vitamin supplement was not demonstrated to reduce overall or cancer-specific mortality, although the authors observed nonsignificant reductions in both.1
Bach PB, Lewis RJ. Multiplicities in the Assessment of Multiple VitaminsIs It Too Soon to Tell Men That Vitamins Prevent Cancer?. JAMA. 2012;308(18):1916–1917. doi:10.1001/jama.2012.53273
* * SCHEDULED MAINTENANCE * *
The JAMA Network Sites will be conducting routine maintenance from 10/20/2017 through 10/21/2017. During this window access to content and authentication may be intermittently available. The JAMA Store will be completely unavailable during the maintenance window.